BioSpace News Archive

Nuvalent, Inc. announced the pricing of its previously announced underwritten public offering of 5,357,143 shares of Class A common stock at a price to the public of $56.00 per share.

Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced new early data in 10 patients with CD20 positive non-Hodgkin lymphoma enrolled in the first three cohorts in an ongoing multicenter Phase 1 study of natural killer (NK) cell therapy candidate GDA-201.

Athersys, Inc. announces it has entered into a warrant exercise inducement offer letter to raise gross proceeds of up to approximately $3.9 million from the exercise of 28,124,590 warrants and received the first tranche payment of $1.5 million from HEALIOS K.K.

Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and nine months ended August 31, 2023.

Apollomics Inc. (Nasdaq: APLM) (the “Company”) today announced that two abstracts detailing vebreltinib data were made available as part of the European Society of Medical Oncology Congress (ESMO) 2023 being held in Madrid, Spain from October 20-24, 2023.

CANbridge Pharmaceuticals Inc. announced that the National Medical Products Administration of China has accepted the New Drug Application for CAN108 for the treatment of cholestatic pruritus in patients two months of age and older with progressive familial intrahepatic cholestasis.

WuXi Biologics announced that it has launched a new proprietary bioprocessing platform WuXiUI™, an ultra-intensified, fed-batch solution that enhances the productivity and quality of multiple different CHO or other mammalian cell lines and product modalities.